Solid papillary mesothelial tumor.
Adult
Aged
Carcinoma, Papillary
/ genetics
Chi-Square Distribution
Cluster Analysis
Cohort Studies
Female
Follow-Up Studies
Gene Expression Regulation, Neoplastic
Humans
In Situ Hybridization, Fluorescence
Incidental Findings
Middle Aged
Mutation
Neoplasms, Mesothelial
/ genetics
Peritoneal Neoplasms
/ genetics
Prognosis
Sequence Analysis, RNA
Signal Transduction
Time Factors
Translocation, Genetic
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
20
06
2021
accepted:
07
08
2021
revised:
06
08
2021
pubmed:
5
9
2021
medline:
2
4
2022
entrez:
4
9
2021
Statut:
ppublish
Résumé
We report nine examples of a previously undescribed type of peritoneal circumscribed nodular mesothelial tumor characterized by nests or sheets of mesothelial cells with sharp cell borders and extremely bland, sometimes grooved, nuclei. In some cases, nests were separated by fibrous bands. All patients were women, age range 30-72 years (median 52 years). All tumors were incidental findings during surgery and grossly were either solitary nodules or a few small nodules on the peritoneal surface. Referring pathologic diagnoses included diffuse malignant mesothelioma, localized malignant mesothelioma, well-differentiated papillary mesothelioma, and adenomatoid tumor. No tumor showed BAP1 loss by immunohistochemistry nor deletion of CDKN2A by FISH. RNA-seq revealed that these tumors clustered together and were distinct from peritoneal diffuse malignant mesotheliomas. Very few mutations or translocations were found, none of them recurrent from tumor to tumor, and no tumor showed an abnormality in any of the genes typically mutated/deleted in diffuse malignant mesothelioma. Array CGH on three cases revealed two with a completely flat profile and one with a small deletion at 3q26-3q28. On follow-up (range 5-60, median 34 months), there were no deaths, no recurrences, and no evidence of metastatic disease nor local spread; one case that initially had scattered nodules on the pelvic peritoneum had the same pattern of nodules at a second look operation 2 years later. We propose the name solid papillary mesothelial tumor for these lesions. These appear to be either benign or very low-grade tumors that need to be separated from malignant mesotheliomas.
Identifiants
pubmed: 34480081
doi: 10.1038/s41379-021-00899-3
pii: S0893-3952(22)00352-0
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
69-76Informations de copyright
© 2021. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.
Références
WHO Classification of Tumours Editorial Board. Thoracic Tumours. WHO Classification of Tumours Series 5th edn, Vol. 5, https://publications.iarc.fr/595 (International Agency for Research on Cancer, 2021).
Wadowski, B., De Rienzo, A. & Bueno, R. The molecular basis of malignant pleural mesothelioma. Thorac Surg. Clin. 30, 383–393 (2020).
doi: 10.1016/j.thorsurg.2020.08.005
Wang, L. M. et al. Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis. Oncotarget 8, 68863–68872 (2017).
doi: 10.18632/oncotarget.20317
Leblay, N. et al. BAP1 is altered by copy number loss, mutation, and/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas. J. Thorac. Oncol. 12, 724–733 (2017).
doi: 10.1016/j.jtho.2016.12.019
Singhi, A. D. et al. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Mod. Pathol. 29, 14–24 (2016).
doi: 10.1038/modpathol.2015.121
Shrestha, R. et al. Well-Differentiated papillary mesothelioma of the peritoneum is genetically distinct from malignant mesothelioma. Cancers (Basel) 12, 1568 (2020).
doi: 10.3390/cancers12061568
Stevers, M. et al. Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42. Mod. Pathol. 32, 88–99 (2019).
doi: 10.1038/s41379-018-0127-2
Goode, B. et al. Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation. Mod. Pathol. 31, 660–673 (2018).
doi: 10.1038/modpathol.2017.153
Itami, H. et al. TRAF7 mutations and immunohistochemical study of uterine adenomatoid tumor compared with malignant mesothelioma. Hum. Pathol. 111, 59–66 (2021).
doi: 10.1016/j.humpath.2021.02.007
Galateau-Salle, F. et al. Comprehensive molecular and pathologic evaluation of transitional mesothelioma assisted by deep learning approach: a multi-institutional study of the International Mesothelioma Panel from the MESOPATH Reference Center. J. Thorac. Oncol. 15, 1037–1053 (2020).
doi: 10.1016/j.jtho.2020.01.025
Marchevsky, A. M. et al. Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel. Mod. Pathol. 33, 281–296 (2020).
doi: 10.1038/s41379-019-0352-3
Hung, Y. P. et al. Molecular characterization of localized pleural mesothelioma. Mod. Pathol. 33, 271–280 (2020).
doi: 10.1038/s41379-019-0330-9